{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:32:47Z","timestamp":1793111567092,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adverse drug events contribute to rising health care costs. Clinical pharmacists can reduce their risks by identifying and solving drug-related problems (DRPs) through medication review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To develop an economic model to determine whether medication reviews performed by clinical pharmacists could lead to a reduction in health care costs associated with the prevention of potential adverse drug events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Two\u00a0pharmacists performed medication reviews during ward rounds in an internal medicine setting over one year. Avoided costs were estimated by monetizing five categories of DRPs (improper drug selection, drug interactions, untreated indications, inadequate dosages, and drug use without an indication). An expert panel assessed potential adverse drug events and their probabilities of occurrence for 20 randomly selected DRPs in each category. The costs of adverse drug events were extracted from internal hospital financial data. A partial economic study from a hospital perspective then\u00a0estimated the annual costs avoided by resolving DRPs\u00a0identified by 3 part-time clinical pharmacists (0.9 full-time equivalent) from 2019 to 2020. The return on investment (ROI)\u00a0of medication review was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The estimated annual avoided costs associated with the potential adverse drug events induced by 676 DRPs detected was \u20ac 304,170. The cost of a 0.9 full-time equivalent clinical pharmacist was \u20ac 112,408. Extrapolated to 1 full-time equivalent, the annual net savings was \u20ac 213,069 or an ROI of 1\u20131.71. Sensitivity analyses showed that the economic model was robust.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This economic model revealed the positive financial impact and favorable return on investment of a medication review intervention performed by clinical pharmacists. These findings should encourage the future deployment of a pharmacist-led adverse drug events prevention program.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-023-01683-w","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T06:03:03Z","timestamp":1707112983000},"page":"496-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-2896","authenticated-orcid":false,"given":"M\u00e9gane","family":"Jermini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fonzo-Christe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Blondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Milaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Stirnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Bonnabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Guignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"1683_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/s1086-5802(16)31229-3","volume":"41","author":"FR Ernst","year":"2001","unstructured":"Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192\u20139. https:\/\/doi.org\/10.1016\/s1086-5802(16)31229-3.","journal-title":"J Am Pharm Assoc"},{"key":"1683_CR2","doi-asserted-by":"publisher","first-page":"e002574","DOI":"10.1136\/bmjopen-2013-002574","volume":"3","author":"H Gyllensten","year":"2013","unstructured":"Gyllensten H, Rehnberg C, J\u00f6nsson AK, et al. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open. 2013;3:e002574. https:\/\/doi.org\/10.1136\/bmjopen-2013-002574.","journal-title":"BMJ Open"},{"key":"1683_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jval.2012.05.007","volume":"15","author":"D Rottenkolber","year":"2012","unstructured":"Rottenkolber D, Hasford J, Stausberg J. Costs of adverse drug events in German Hospitals\u2014a microcosting study. Value Health. 2012;15:868\u201375. https:\/\/doi.org\/10.1016\/j.jval.2012.05.007.","journal-title":"Value Health"},{"key":"1683_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1001\/jama.2016.16201","volume":"316","author":"N Shehab","year":"2016","unstructured":"Shehab N, Lovegrove MC, Geller AI, et al. US emergency department visits for outpatient adverse drug events, 2013\u20132014. JAMA. 2016;316:2115\u201325. https:\/\/doi.org\/10.1001\/jama.2016.16201.","journal-title":"JAMA"},{"key":"1683_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.4414\/smw.2004.10801","volume":"134","author":"B Hardmeier","year":"2004","unstructured":"Hardmeier B, Braunschweig S, Cavallaro M, et al. Adverse drug events caused by medication errors in medical inpatients. Swiss Med Wkly. 2004;134:664\u201370. https:\/\/doi.org\/10.4414\/smw.2004.10801.","journal-title":"Swiss Med Wkly"},{"key":"1683_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1472-6963-14-125","volume":"14","author":"J Stausberg","year":"2014","unstructured":"Stausberg J. International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA. BMC Health Serv Res. 2014;14:125. https:\/\/doi.org\/10.1186\/1472-6963-14-125.","journal-title":"BMC Health Serv Res"},{"key":"1683_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/archinte.166.5.565","volume":"166","author":"JL Schnipper","year":"2006","unstructured":"Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006;166:565\u201371. https:\/\/doi.org\/10.1001\/archinte.166.5.565.","journal-title":"Arch Intern Med"},{"key":"1683_CR8","doi-asserted-by":"publisher","first-page":"e7883","DOI":"10.1097\/MD.0000000000007883","volume":"96","author":"C-C Chen","year":"2017","unstructured":"Chen C-C, Hsiao F-Y, Shen L-J, et al. The cost-saving effect and prevention of medication errors by clinical pharmacist intervention in a nephrology unit. Medicine (Baltimore). 2017;96:e7883. https:\/\/doi.org\/10.1097\/MD.0000000000007883.","journal-title":"Medicine (Baltimore)"},{"key":"1683_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1078155219875806","volume":"26","author":"P-Z Chen","year":"2020","unstructured":"Chen P-Z, Wu C-C, Huang C-F. Clinical and economic impact of clinical pharmacist intervention in a hematology unit. J Oncol Pharm Pract. 2020;26:866\u201372. https:\/\/doi.org\/10.1177\/1078155219875806.","journal-title":"J Oncol Pharm Pract"},{"key":"1683_CR10","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.sapharm.2018.10.006","volume":"15","author":"DM Dawoud","year":"2019","unstructured":"Dawoud DM, Smyth M, Ashe J, et al. Effectiveness and cost effectiveness of pharmacist input at the ward level: a systematic review and meta-analysis. Res Soc Adm Pharm. 2019;15:1212\u201322. https:\/\/doi.org\/10.1016\/j.sapharm.2018.10.006.","journal-title":"Res Soc Adm Pharm"},{"key":"1683_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.sapharm.2019.10.014","volume":"16","author":"S English","year":"2020","unstructured":"English S, Hort A, Sullivan N, et al. Is ward round participation by clinical pharmacists a valuable use of time and money? A time and motion study. Res Soc Adm Pharm. 2020;16:1026\u201332. https:\/\/doi.org\/10.1016\/j.sapharm.2019.10.014.","journal-title":"Res Soc Adm Pharm"},{"key":"1683_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.9740\/mhc.2016.09.242","volume":"6","author":"A Gunterus","year":"2016","unstructured":"Gunterus A, Lopchuk S, Dunn C, et al. Quantitative and economic analysis of clinical pharmacist interventions during rounds in an acute care psychiatric hospital. Ment Health Clin. 2016;6:242\u20137. https:\/\/doi.org\/10.9740\/mhc.2016.09.242.","journal-title":"Ment Health Clin"},{"key":"1683_CR13","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1060028017712725","volume":"51","author":"CR Rodrigues","year":"2017","unstructured":"Rodrigues CR, Harrington AR, Murdock N, et al. Effect of pharmacy-supported transition-of-care interventions on 30-day readmissions: a systematic review and meta-analysis. Ann Pharmacother. 2017;51:866\u201389. https:\/\/doi.org\/10.1177\/1060028017712725.","journal-title":"Ann Pharmacother"},{"key":"1683_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.japh.2019.06.020","volume":"60","author":"L Bethishou","year":"2020","unstructured":"Bethishou L, Herzik K, Fang N, et al. The impact of the pharmacist on continuity of care during transitions of care: a systematic review. J Am Pharm Assoc. 2020;60:163-177.e2. https:\/\/doi.org\/10.1016\/j.japh.2019.06.020.","journal-title":"J Am Pharm Assoc"},{"key":"1683_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/j.1875-9114.1996.tb03049.x","volume":"16","author":"GT Schumock","year":"1996","unstructured":"Schumock GT, Meek PD, Ploetz PA, et al. Economic evaluations of clinical pharmacy services\u20141988\u20131995. Pharmacother J Hum Pharmacol Drug Ther. 1996;16:1188\u2013208. https:\/\/doi.org\/10.1002\/j.1875-9114.1996.tb03049.x.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"1683_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1592\/phco.23.1.113.31910","volume":"23","author":"GT Schumock","year":"2003","unstructured":"Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996\u20132000. Pharmacother J Hum Pharmacol Drug Ther. 2003;23:113\u201332. https:\/\/doi.org\/10.1592\/phco.23.1.113.31910.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"1683_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1592\/phco.29.1.128","volume":"29","author":"A Perez","year":"2009","unstructured":"Perez A, Doloresco F, Hoffman JM, et al. Economic evaluations of clinical pharmacy services: 2001\u20132005. Pharmacother J Hum Pharmacol Drug Ther. 2009;29:128\u2013128. https:\/\/doi.org\/10.1592\/phco.29.1.128.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"1683_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/phar.1414","volume":"34","author":"DR Touchette","year":"2014","unstructured":"Touchette DR, Doloresco F, Suda KJ, et al. Economic evaluations of clinical pharmacy services: 2006\u20132010. Pharmacother J Hum Pharmacol Drug Ther. 2014;34:771\u201393. https:\/\/doi.org\/10.1002\/phar.1414.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"1683_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11096-014-0008-9","volume":"36","author":"J Gallagher","year":"2014","unstructured":"Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36:1101\u201314. https:\/\/doi.org\/10.1007\/s11096-014-0008-9.","journal-title":"Int J Clin Pharm"},{"key":"1683_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/ajhp\/54.4.392","volume":"54","author":"AH Mutnick","year":"1997","unstructured":"Mutnick AH, Sterba KJ, Peroutka JA, et al. Cost savings and avoidance from clinical interventions. Am J Health Syst Pharm. 1997;54:392\u20136.","journal-title":"Am J Health Syst Pharm"},{"key":"1683_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ajhp\/58.9.784","volume":"58","author":"TW Nesbit","year":"2001","unstructured":"Nesbit TW, Shermock KM, Bobek MB, et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health Syst Pharm. 2001;58:784\u201390.","journal-title":"Am J Health Syst Pharm"},{"key":"1683_CR22","first-page":"10","volume":"76","author":"BE Bosma","year":"2018","unstructured":"Bosma BE. Pharmacist interventions during patient rounds in two intensive care units: clinical and financial impact. Neth J Med. 2018;76:10.","journal-title":"Neth J Med"},{"key":"1683_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.18553\/jmcp.2019.25.3.411","volume":"25","author":"S Jacob","year":"2019","unstructured":"Jacob S, Britt RB, Bryan WE, et al. Economic outcomes associated with safety interventions by a pharmacist-adjudicated prior authorization consult service. J Manag Care Spec Pharm. 2019;25:411\u20136. https:\/\/doi.org\/10.18553\/jmcp.2019.25.3.411.","journal-title":"J Manag Care Spec Pharm"},{"key":"1683_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40273-017-0529-x","volume":"35","author":"S Simoens","year":"2017","unstructured":"Simoens S, Jacobs I, Popovian R, et al. Assessing the value of biosimilars: a review of the role of budget impact analysis. Pharmacoeconomics. 2017;35:1047\u201362. https:\/\/doi.org\/10.1007\/s40273-017-0529-x.","journal-title":"Pharmacoeconomics"},{"key":"1683_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/ejhpharm-2018-001733","volume":"27","author":"P Bonnabry","year":"2020","unstructured":"Bonnabry P, Fran\u00e7ois O. Return on investment: a practical calculation tool to convince your institution. Eur J Hosp Pharm. 2020;27:111\u20133. https:\/\/doi.org\/10.1136\/ejhpharm-2018-001733.","journal-title":"Eur J Hosp Pharm"},{"key":"1683_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/intqhc\/mzy155","volume":"31","author":"S Berdot","year":"2019","unstructured":"Berdot S, Blanc C, Chevalier D, et al. Impact of drug storage systems: a quasi-experimental study with and without an automated-drug dispensing cabinet. Int J Qual Health Care. 2019;31:225\u201330. https:\/\/doi.org\/10.1093\/intqhc\/mzy155.","journal-title":"Int J Qual Health Care"},{"key":"1683_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.6061\/clinics\/2017(10)07","volume":"72","author":"D de Carvalho","year":"2017","unstructured":"de Carvalho D, Alvim-Borges JL, Toscano CM. Impact assessment of an automated drug-dispensing system in a tertiary hospital. Clinics. 2017;72:629\u201336. https:\/\/doi.org\/10.6061\/clinics\/2017(10)07.","journal-title":"Clinics"},{"key":"1683_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.jval.2017.03.001","volume":"20","author":"BW Ris\u00f8r","year":"2017","unstructured":"Ris\u00f8r BW, Lisby M, S\u00f8rensen J. Cost-effectiveness analysis of an automated medication system implemented in a Danish Hospital setting. Value Health. 2017;20:886\u201393. https:\/\/doi.org\/10.1016\/j.jval.2017.03.001.","journal-title":"Value Health"},{"key":"1683_CR29","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/jep.12289","volume":"20","author":"BOM Claus","year":"2014","unstructured":"Claus BOM, Robays H, Decruyenaere J, et al. Expected net benefit of clinical pharmacy in intensive care medicine: a randomized interventional comparative trial with matched before-and-after groups. J Eval Clin Pract. 2014;20:1172\u20139. https:\/\/doi.org\/10.1111\/jep.12289.","journal-title":"J Eval Clin Pract"},{"key":"1683_CR30","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2146\/ajhp060674","volume":"64","author":"BJ Kopp","year":"2007","unstructured":"Kopp BJ, Mrsan M, Erstad BL, et al. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64:2483\u20137. https:\/\/doi.org\/10.2146\/ajhp060674.","journal-title":"Am J Health Syst Pharm"},{"key":"1683_CR31","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1093\/ajhp\/59.21.2070","volume":"59","author":"AJ Lee","year":"2002","unstructured":"Lee AJ, Boro MS, Knapp KK, et al. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health Syst Pharm. 2002;59:2070\u20137.","journal-title":"Am J Health Syst Pharm"},{"key":"1683_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00019053-200018050-00005","volume":"18","author":"SI Benrimoj","year":"2000","unstructured":"Benrimoj SI, Langford JH, Berry G, et al. Economic impact of increased clinical intervention rates in community pharmacy. Pharmacoeconomics. 2000;18:459\u201368. https:\/\/doi.org\/10.2165\/00019053-200018050-00005.","journal-title":"Pharmacoeconomics"},{"key":"1683_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1331\/JAPhA.2015.14062","volume":"55","author":"H-A Truong","year":"2015","unstructured":"Truong H-A, Nicole Groves C, Congdon HB, et al. Potential cost savings of medication therapy management in safety-net clinics. J Am Pharm Assoc. 2015;55:269\u201372. https:\/\/doi.org\/10.1331\/JAPhA.2015.14062.","journal-title":"J Am Pharm Assoc"},{"key":"1683_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1078155216671189","volume":"24","author":"LA Randolph","year":"2018","unstructured":"Randolph LA, Walker CK, Nguyen AT, et al. Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center. J Oncol Pharm Pract. 2018;24:3\u20138. https:\/\/doi.org\/10.1177\/1078155216671189.","journal-title":"J Oncol Pharm Pract"},{"key":"1683_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/0897190011418512","volume":"25","author":"C Chinthammit","year":"2012","unstructured":"Chinthammit C, Armstrong EP, Warholak TL. A cost-effectiveness evaluation of hospital discharge counseling by pharmacists. J Pharm Pract. 2012;25:201\u20138. https:\/\/doi.org\/10.1177\/0897190011418512.","journal-title":"J Pharm Pract"},{"key":"1683_CR36","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1007\/s11096-018-0733-6","volume":"40","author":"J-P Jourdan","year":"2018","unstructured":"Jourdan J-P, Muzard A, Goyer I, et al. Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital. Int J Clin Pharm. 2018;40:1474\u201381. https:\/\/doi.org\/10.1007\/s11096-018-0733-6.","journal-title":"Int J Clin Pharm"},{"key":"1683_CR37","doi-asserted-by":"publisher","first-page":"e007367","DOI":"10.1136\/bmjopen-2014-007367","volume":"5","author":"A Ahmad","year":"2015","unstructured":"Ahmad A, Weston PJ, Ahmad M, et al. A cost-benefit analysis of twice-daily consultant ward rounds and clinical input on investigation and pharmacy costs in a major teaching hospital in the UK. BMJ Open. 2015;5:e007367. https:\/\/doi.org\/10.1136\/bmjopen-2014-007367.","journal-title":"BMJ Open"},{"key":"1683_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40545-016-0073-7","volume":"10","author":"D Yasunaga","year":"2016","unstructured":"Yasunaga D, Tasaka Y, Murakami S, et al. Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japan. J Pharm Policy Pract. 2016;10:2. https:\/\/doi.org\/10.1186\/s40545-016-0073-7.","journal-title":"J Pharm Policy Pract"},{"key":"1683_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4321\/s1886-36552009000200003","volume":"7","author":"S Saokaew","year":"2009","unstructured":"Saokaew S, Maphanta S, Thangsomboon P. Impact of pharmacist\u2019s interventions on cost of drug therapy in intensive care unit. Pharm Pract. 2009;7:81\u20137.\u00a0https:\/\/doi.org\/10.4321\/s1886-36552009000200003.","journal-title":"Pharm Pract"},{"key":"1683_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12913-018-3306-4","volume":"18","author":"Z Bao","year":"2018","unstructured":"Bao Z, Ji C, Hu J, et al. Clinical and economic impact of pharmacist interventions on sampled outpatient prescriptions in a Chinese teaching hospital. BMC Health Serv Res. 2018;18:519. https:\/\/doi.org\/10.1186\/s12913-018-3306-4.","journal-title":"BMC Health Serv Res"},{"key":"1683_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40780-018-0125-z","volume":"4","author":"Y Tasaka","year":"2018","unstructured":"Tasaka Y, Tanaka A, Yasunaga D, et al. Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan. J Pharm Health Care Sci. 2018;4:33. https:\/\/doi.org\/10.1186\/s40780-018-0125-z.","journal-title":"J Pharm Health Care Sci"},{"key":"1683_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11096-015-0245-6","volume":"38","author":"Y Tasaka","year":"2016","unstructured":"Tasaka Y, Yasunaga D, Tanaka M, et al. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan. Int J Clin Pharm. 2016;38:321\u20139. https:\/\/doi.org\/10.1007\/s11096-015-0245-6.","journal-title":"Int J Clin Pharm"},{"key":"1683_CR43","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s11096-018-0696-7","volume":"40","author":"N Griese-Mammen","year":"2018","unstructured":"Griese-Mammen N, Hersberger KE, Messerli M, et al. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018;40:1199\u2013208. https:\/\/doi.org\/10.1007\/s11096-018-0696-7.","journal-title":"Int J Clin Pharm"},{"key":"1683_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/ajhp\/47.3.533","volume":"47","author":"CD Hepler","year":"1990","unstructured":"Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533\u201343. https:\/\/doi.org\/10.1093\/ajhp\/47.3.533.","journal-title":"Am J Hosp Pharm"},{"key":"1683_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","volume":"274","author":"DW Bates","year":"1995","unstructured":"Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274:29\u201334. https:\/\/doi.org\/10.1001\/jama.1995.03530010043033.","journal-title":"JAMA"},{"key":"1683_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ejim.2015.05.012","volume":"26","author":"B Guignard","year":"2015","unstructured":"Guignard B, Bonnabry P, Perrier A, et al. Drug-related problems identification in general internal medicine: the impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26:399\u2013406. https:\/\/doi.org\/10.1016\/j.ejim.2015.05.012.","journal-title":"Eur J Intern Med"},{"key":"1683_CR47","unstructured":"Proc\u00e9dure de certification REKOLE\u00ae. https:\/\/www.hplus.ch\/fr\/comptabilite\/proceduredecertificationrekoler\/. Accessed 6 Jan 2019."},{"key":"1683_CR48","unstructured":"World Health Organization International Classification of Diseases (ICD). https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases. Accessed 14 Sep 2023."},{"key":"1683_CR49","unstructured":"World Health Organization ICD Update Platform. https:\/\/icd.who.int\/icd10updateplatform\/. Accessed 14 May 2020."},{"key":"1683_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/ijpp.12058","volume":"22","author":"HL Neville","year":"2014","unstructured":"Neville HL, Chevalier B, Daley C, et al. Clinical benefits and economic impact of post-surgical care provided by pharmacists in a Canadian hospital. Int J Pharm Pract. 2014;22:216\u201322. https:\/\/doi.org\/10.1111\/ijpp.12058.","journal-title":"Int J Pharm Pract"},{"key":"1683_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1472-6963-14-177","volume":"14","author":"J Gallagher","year":"2014","unstructured":"Gallagher J, Byrne S, Woods N, et al. Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 2014;14:177. https:\/\/doi.org\/10.1186\/1472-6963-14-177.","journal-title":"BMC Health Serv Res"},{"key":"1683_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40266-016-0348-3","volume":"33","author":"J Gallagher","year":"2016","unstructured":"Gallagher J, O\u2019Sullivan D, McCarthy S, et al. Structured pharmacist review of medication in older hospitalised patients: a cost-effectiveness analysis. Drugs Aging. 2016;33:285\u201394. https:\/\/doi.org\/10.1007\/s40266-016-0348-3.","journal-title":"Drugs Aging"},{"key":"1683_CR53","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1310\/hpj4809-744","volume":"48","author":"S Calloway","year":"2013","unstructured":"Calloway S, Akilo HA, Bierman K. Impact of a clinical decision support system on pharmacy clinical interventions, documentation efforts, and costs. Hosp Pharm. 2013;48:744\u201352. https:\/\/doi.org\/10.1310\/hpj4809-744.","journal-title":"Hosp Pharm"},{"key":"1683_CR54","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1186\/s12913-020-05688-3","volume":"20","author":"D Lewkowicz","year":"2020","unstructured":"Lewkowicz D, Wohlbrandt A, Boettinger E. Economic impact of clinical decision support interventions based on electronic health records. BMC Health Serv Res. 2020;20:871. https:\/\/doi.org\/10.1186\/s12913-020-05688-3.","journal-title":"BMC Health Serv Res"},{"key":"1683_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/ejhpharm-2020-002667","volume":"30","author":"C Skalafouris","year":"2021","unstructured":"Skalafouris C, Samer C, Stirnemann J, et al. Electronic monitoring of potential adverse drug events related to lopinavir\/ritonavir and hydroxychloroquine during the first wave of COVID-19. Eur J Hosp Pharm. 2021;30:113\u20136. https:\/\/doi.org\/10.1136\/ejhpharm-2020-002667.","journal-title":"Eur J Hosp Pharm"},{"key":"1683_CR56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11096-021-01356-6","volume":"44","author":"E D\u2019hulster","year":"2022","unstructured":"D\u2019hulster E, Quintens C, Bisschops R, et al. Cost-effectiveness of check of medication appropriateness: methodological approach. Int J Clin Pharm. 2022;44:399\u2013408. https:\/\/doi.org\/10.1007\/s11096-021-01356-6.","journal-title":"Int J Clin Pharm"},{"key":"1683_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13613-018-0361-2","volume":"8","author":"LBE Bosma","year":"2018","unstructured":"Bosma LBE, Hunfeld NGM, Quax RAM, et al. The effect of a medication reconciliation program in two intensive care units in the Netherlands: a prospective intervention study with a before and after design. Ann Intensive Care. 2018;8:19. https:\/\/doi.org\/10.1186\/s13613-018-0361-2.","journal-title":"Ann Intensive Care"},{"key":"1683_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.sapharm.2018.05.006","volume":"15","author":"M Sj\u00f6lander","year":"2019","unstructured":"Sj\u00f6lander M, Lindholm L, Pfister B, et al. Impact of clinical pharmacist engagement in ward teams on the number of drug-related readmissions among older patients with dementia or cognitive impairment: an economic evaluation. Res Soc Adm Pharm. 2019;15:287\u201391. https:\/\/doi.org\/10.1016\/j.sapharm.2018.05.006.","journal-title":"Res Soc Adm Pharm"},{"key":"1683_CR59","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s11096-020-01059-4","volume":"42","author":"M Odeh","year":"2020","unstructured":"Odeh M, Scullin C, Hogg A, et al. A novel approach to medicines optimisation post-discharge from hospital: pharmacist-led medicines optimisation clinic. Int J Clin Pharm. 2020;42:1036\u201349. https:\/\/doi.org\/10.1007\/s11096-020-01059-4.","journal-title":"Int J Clin Pharm"},{"key":"1683_CR60","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/jep.13209","volume":"26","author":"RA Al-Qudah","year":"2020","unstructured":"Al-Qudah RA, Al-Badriyeh D, Al-Ali FM, et al. Cost-benefit analysis of clinical pharmacist intervention in preventing adverse drug events in the general chronic diseases outpatients. J Eval Clin Pract. 2020;26:115\u201324. https:\/\/doi.org\/10.1111\/jep.13209.","journal-title":"J Eval Clin Pract"},{"key":"1683_CR61","doi-asserted-by":"publisher","first-page":"e000329","DOI":"10.1136\/bmjopen-2011-000329","volume":"2","author":"SM Wallerstedt","year":"2012","unstructured":"Wallerstedt SM, Bladh L, Ramsberg J. A cost-effectiveness analysis of an in-hospital clinical pharmacist service. BMJ Open. 2012;2:e000329. https:\/\/doi.org\/10.1136\/bmjopen-2011-000329.","journal-title":"BMJ Open"},{"key":"1683_CR62","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S0140-6736(11)61817-5","volume":"379","author":"AJ Avery","year":"2012","unstructured":"Avery AJ, Rodgers S, Cantrill JA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. The Lancet. 2012;379:1310\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(11)61817-5.","journal-title":"The Lancet"},{"key":"1683_CR63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2753.2008.01000.x","volume":"15","author":"J Karnon","year":"2009","unstructured":"Karnon J, Campbell F, Czoski-Murray C. Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). J Eval Clin Pract. 2009;15:299\u2013306. https:\/\/doi.org\/10.1111\/j.1365-2753.2008.01000.x.","journal-title":"J Eval Clin Pract"},{"key":"1683_CR64","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.sapharm.2018.03.062","volume":"15","author":"MJ Twigg","year":"2019","unstructured":"Twigg MJ, Wright D, Barton G, et al. The pharmacy care plan service: evaluation and estimate of cost-effectiveness. Res Soc Adm Pharm. 2019;15:84\u201392. https:\/\/doi.org\/10.1016\/j.sapharm.2018.03.062.","journal-title":"Res Soc Adm Pharm"},{"key":"1683_CR65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40273-015-0270-2","volume":"33","author":"F J\u00f3dar-S\u00e1nchez","year":"2015","unstructured":"J\u00f3dar-S\u00e1nchez F, Malet-Larrea A, Mart\u00edn JJ, et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015;33:599\u2013610. https:\/\/doi.org\/10.1007\/s40273-015-0270-2.","journal-title":"Pharmacoeconomics"},{"key":"1683_CR66","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s10198-016-0853-7","volume":"18","author":"A Malet-Larrea","year":"2017","unstructured":"Malet-Larrea A, Goyenechea E, Gastelurrutia MA, et al. Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients. Eur J Health Econ. 2017;18:1069\u201378. https:\/\/doi.org\/10.1007\/s10198-016-0853-7.","journal-title":"Eur J Health Econ"},{"key":"1683_CR67","doi-asserted-by":"publisher","first-page":"e018722","DOI":"10.1136\/bmjopen-2017-018722","volume":"7","author":"RA Elliott","year":"2017","unstructured":"Elliott RA, Lee CY, Beanland C, et al. Development of a clinical pharmacy model within an Australian home nursing service using co-creation and participatory action research: the Visiting Pharmacist (ViP) study. BMJ Open. 2017;7:e018722. https:\/\/doi.org\/10.1136\/bmjopen-2017-018722.","journal-title":"BMJ Open"},{"key":"1683_CR68","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1345\/aph.1Q520","volume":"46","author":"F Karapinar-\u00c7arkit","year":"2012","unstructured":"Karapinar-\u00c7arkit F, Borgsteede SD, Zoer J, et al. Effect of medication reconciliation on medication costs after hospital discharge in relation to hospital pharmacy labor costs. Ann Pharmacother. 2012;46:329\u201338. https:\/\/doi.org\/10.1345\/aph.1Q520.","journal-title":"Ann Pharmacother"},{"key":"1683_CR69","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1592\/phco.20.15.1149.34590","volume":"20","author":"DC Malone","year":"2012","unstructured":"Malone DC, Carter BL, Billups SJ, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Pharmacother J Hum Pharmacol Drug Ther. 2012;20:1149\u201358. https:\/\/doi.org\/10.1592\/phco.20.15.1149.34590.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"1683_CR70","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/bcp.14095","volume":"85","author":"P-L Hung","year":"2019","unstructured":"Hung P-L, Chen J-Y, Chen M-T, et al. The impact of a medication reconciliation programme at geriatric hospital admission: a pre-\/postintervention study. Br J Clin Pharmacol. 2019;85:2614\u201322. https:\/\/doi.org\/10.1111\/bcp.14095.","journal-title":"Br J Clin Pharmacol"},{"key":"1683_CR71","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1227\/01.NEU.0000347090.22818.35","volume":"65","author":"KA Weant","year":"2009","unstructured":"Weant KA, Armitstead JA, Ladha AM, et al. Cost effectiveness of a clinical pharmacist on a neurosurgical team. Neurosurgery. 2009;65:946\u201351. https:\/\/doi.org\/10.1227\/01.NEU.0000347090.22818.35.","journal-title":"Neurosurgery"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01683-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T11:06:04Z","timestamp":1711191964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01683-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01683-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3127564\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}